XEVUDY

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug XEVUDY contains one active pharmaceutical ingredient (API):

1	Sotrovimab UNII 1MTK0BPN8V - SOTROVIMAB
	Sotrovimab is a dual action, engineered human IgG1 mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. It is used for the treatment of symptomatic adults and adolescents with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.
	Read more about Sotrovimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XEVUDY Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD	Antiviral monoclonal antibodies	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins
Discover more medicines within J06BD

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1872817
ES	Centro de información online de medicamentos de la AEMPS	1211562001
FR	Base de données publique des médicaments	62519824
IT	Agenzia del Farmaco	049812011
JP	医薬品医療機器総合機構	62504A4A1023
LT	Valstybinė vaistų kontrolės tarnyba	1093887
PL	Rejestru Produktów Leczniczych	100463322
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68344001